Is Exenatide the Next Big Thing in Parkinson's Disease?
A recent study by Aviles-Olmos and colleagues suggests that 12 months of treatment with the glucagon-like peptide-1 receptor agonist exenatide improves motor and cognitive symptoms in Parkinson's disease (PD), and that the effect persists as long as 12 months after termination of the treatment. Due...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publishing
2014-08-01
|
| Edice: | Journal of Parkinson’s Disease |
| On-line přístup: | https://doi.org/10.3233/JPD-149001 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|